SEC Filings


Form S-1/A
Raptor Pharmaceutical Corp filed this Form S-1/A on 05/07/10
Document Outline
Entire Document (4831.4 KB)
Subdocument 1 - S-1/A - RAPTOR PRE-EFFECTIVE AMENDMENT TO S1 050610
Page 1 - As filed with the Securities and Exchange Commission on May 7, 2010
Page 2 - CALCULATION OF REGISTRATION FEE
Page 3 - The information in this prospectus is not complete and may be changed. We may not sell these securit
Page 4 - TABLE OF CONTENTS
Page 5 - PROSPECTUS SUMMARY
Page 6 - Other Clinical-Stage Product Candidates
Page 7 - Purchase of Convivia™
Page 8 - Company History
Page 9 - Issuance of Common Stock Pursuant to Stock Option Exercises
Page 10 - Post-Merger Financing - Registered Direct Offering
Page 11 - Securities Offered
Page 12 - N/A
Page 13 - RISK FACTORS
Page 14 - N/A
Page 15 - The current disruptions in the financial markets could affect our ability to obtain financing on fav
Page 16 - If we are limited in our ability to utilize acquired or licensed technologies, we may be unable to d
Page 17 - If we do not achieve our projected development goals in the time frames we announce and expect, the
Page 18 - N/A
Page 19 - N/A
Page 20 - If we fail to obtain or maintain orphan drug exclusivity for some of our drug product candidates, ou
Page 21 - Because the target patient populations for some of our products are small, we must achieve significa
Page 22 - N/A
Page 23 - Companies and universities that have licensed product candidates to us for research, clinical develo
Page 24 - Our success depends on our ability to manage our growth.
Page 25 - We may be required to suspend, repeat or terminate our clinical trials if they do not meet regulator
Page 26 - N/A
Page 27 - N/A
Page 28 - Risks Related to Our Common Stock
Page 29 - N/A
Page 30 - Because we do not intend to pay any cash dividends on our common stock, investors will benefit from
Page 31 - N/A
Page 32 - An adverse determination, if any, in the class action suit in which we are a defendant, or our inabi
Page 33 - Anti-takeover provisions under Delaware law, in our stockholder rights plan and in our certificate o
Page 34 - FORWARD-LOOKING STATEMENTS
Page 35 - N/A
Page 36 - USE OF PROCEEDS
Page 37 - MARKET PRICE AND DIVIDEND INFORMATION
Page 38 - DESCRIPTION OF BUSINESS
Page 39 - Future Activities
Page 40 - Development of DR Cysteamine for the Potential Treatment of Non-Alcoholic Steatohepatitis or NASH
Page 41 - Other Clinical-Stage Product Candidates
Page 42 - Preclinical Product Candidates
Page 43 - NeuroTrans™ for the Potential Treatment of Diseases Affecting the Brain
Page 44 - Other Development Areas
Page 45 - Purchase of DR Cysteamine
Page 46 - Competition
Page 47 - Migraine
Page 48 - Hepatitis
Page 49 - Thrombotic Disorder
Page 50 - N/A
Page 51 - N/A
Page 52 - Scientific Advisory Board
Page 53 - Jerry Schneider, M.D. Jerry Schneider, M.D
Page 54 - Compliance with Environmental Laws
Page 55 - SELECTED HISTORICAL CONSOLIDATED FINANCIAL AND OPERATING INFORMATION FOR RAPTOR
Page 56 - February 28, 2010 (unaudited)
Page 57 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 58 - Fixed Assets
Page 59 - Stock-Based Compensation
Page 60 - Results of Operations
Page 61 - Research and Development
Page 62 - Current Status of Major Programs
Page 63 - Reason for Variance
Page 64 - Interest Income
Page 65 - Major Program (stage of development)
Page 66 - Years ended August 31, 2008 and 2007
Page 67 - N/A
Page 68 - N/A
Page 69 - Officer and Employee Compensation
Page 70 - Contractual Obligations with Thomas E. Daley (assignee of the dissolved Convivia, Inc.)
Page 71 - N/A
Page 72 - Contractual Obligations with UCSD
Page 73 - Off-Balance Sheet Arrangements
Page 74 - Collaborative Agreement
Page 75 - Derivatives and Hedging
Page 76 - Transfers and Servicing (Statement No. 166, Accounting for Transfers of Financial Assets — an amendm
Page 77 - DESCRIPTION OF PROPERTY
Page 78 - MANAGEMENT
Page 79 - Erich Sager
Page 80 - Meetings and Committees of the Board of Directors
Page 81 - Raptor Pharmaceuticals Corp.
Page 82 - N/A
Page 83 - Independence of Our Board of Directors
Page 84 - N/A
Page 85 - Name
Page 86 - N/A
Page 87 - Relationships Among Executive Officers and Directors
Page 88 - N/A
Page 89 - EXECUTIVE COMPENSATION
Page 90 - Elements of Compensation
Page 91 - Raptor Pharmaceuticals Corp.
Page 92 - N/A
Page 93 - Restricted Stock and Restricted Stock Units
Page 94 - Perquisites
Page 95 - Employment Agreements
Page 96 - N/A
Page 97 - Raptor Pharmaceuticals Corp.
Page 98 - Equity Incentive Plan
Page 99 - Benchmarking and Consultants
Page 100 - Raptor Pharmaceuticals Corp.
Page 101 - Stock Option Grants and Exercises During the Fiscal Year Ended August 31, 2009
Page 102 - Grants of Plan-Based Awards Table
Page 103 - Raptor Pharmaceuticals Corp.
Page 104 - N/A
Page 105 - Executive Payments Upon Termination
Page 106 - Todd C. Zankel, Ph.D.
Page 107 - Ted Daley
Page 108 - Compensation Committee Interlocks and Insider Participation
Page 109 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Page 110 - SELLING STOCKHOLDER
Page 111 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Page 112 - PLAN OF DISTRIBUTION
Page 113 - N/A
Page 114 - DESCRIPTION OF SECURITIES
Page 115 - N/A
Page 116 - Transfer Agent
Page 117 - N/A
Page 118 - N/A
Page 119 - THE TRANSACTION
Page 120 - Minimum Purchase Price
Page 121 - Assumed
Page 122 - LEGAL MATTERS
Page 123 - WHERE YOU CAN FIND MORE INFORMATION
Page 124 - Information on Our Website
Page 125 - Unaudited Financial Statements
Page 126 - Raptor Pharmaceutical Corp.
Page 127 - N/A
Page 128 - N/A
Page 129 - N/A
Page 130 - RAPTOR PHARMACEUTICAL CORP.
Page 131 - N/A
Page 132 - N/A
Page 133 - N/A
Page 134 - N/A
Page 135 - N/A
Page 136 - N/A
Page 137 - N/A
Page 138 - N/A
Page 139 - N/A
Page 140 - N/A
Page 141 - N/A
Page 142 - N/A
Page 143 - N/A
Page 144 - N/A
Page 145 - N/A
Page 146 - N/A
Page 147 - N/A
Page 148 - N/A
Page 149 - N/A
Page 150 - N/A
Page 151 - N/A
Page 152 - N/A
Page 153 - N/A
Page 154 - N/A
Page 155 - N/A
Page 156 - N/A
Page 157 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 158 - Raptor Pharmaceuticals Corp.
Page 159 - N/A
Page 160 - N/A
Page 161 - N/A
Page 162 - N/A
Page 163 - N/A
Page 164 - N/A
Page 165 - N/A
Page 166 - N/A
Page 167 - RAPTOR PHARMACEUTICALS CORP.
Page 168 - N/A
Page 169 - N/A
Page 170 - N/A
Page 171 - N/A
Page 172 - N/A
Page 173 - N/A
Page 174 - N/A
Page 175 - N/A
Page 176 - N/A
Page 177 - N/A
Page 178 - N/A
Page 179 - N/A
Page 180 - N/A
Page 181 - N/A
Page 182 - N/A
Page 183 - N/A
Page 184 - N/A
Page 185 - N/A
Page 186 - N/A
Page 187 - N/A
Page 188 - N/A
Page 189 - N/A
Page 190 - (14) SUBSEQUENT EVENTS
Page 191 - RAPTOR PHARMACEUTICALS CORP.
Page 192 - Part II
Page 193 - Item 15. Recent Sales of Unregistered Securities
Page 194 - RPC’s Common Stock Issued Pursuant to RPC’s Warrant Exercises
Page 195 - N/A
Page 196 - N/A
Page 197 - August 2009 private placement security holder
Page 198 - Other RPC Common Stock Issuances
Page 199 - N/A
Page 200 - Other Issuances of RPC Warrants
Page 201 - Issuances of TorreyPines Therapeutics, Inc. Warrants
Page 202 - Item 16. Exhibits and Financial Statement Schedules
Page 203 - 4.17 *
Page 204 - 10.27**
Page 205 - Item 17. Undertakings
Page 206 - N/A
Page 207 - SIGNATURES
Page 208 - EXHIBIT INDEX
Page 209 - 4.18 *
Page 210 - 10.28**
Subdocument 2 - EX-23.1 - AUDITOR CONSENT
Page 1 - EXHIBIT 23.1
Page 2 - N/A